CAPR Stock Draws Bullish Calls As FDA Countdown Nears

Capricor Therapeutics Inc. surged as positive clinical and partnership news fueled momentum; stocks have been trading up by 97.62 percent.

Live Update At 07:48:01 EDT: On Friday, August 14, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 97.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CAPR has traded like a biotech rollercoaster. In late July, Capricor Therapeutics shares collapsed from roughly $19–$20 into the mid‑single digits after the FDA advisory committee pushback, a drop of around 70% in days. Since then, the chart shows CAPR grinding sideways between about $3.80 and $4.70, with recent daily closes clustered near $4.20. That tells traders the panic phase cooled, but strong conviction buying has not yet returned.

Under the hood, Capricor Therapeutics is still pre‑revenue. The latest report shows no sales, a net loss of about $33.9M for the quarter, and negative operating cash flow near $29.3M. Those numbers confirm CAPR is burning cash to push deramiocel toward market. The key comfort: an estimated ~$238M cash and investments and a current ratio around 8.4, which signals a very strong near‑term balance sheet.

Valuation metrics back up that picture. CAPR trades at roughly 0.9x book value, unusual for a late‑stage biotech leaning into a pivotal FDA decision. Returns on equity and assets are deeply negative, as expected for a development‑stage name. For traders, that all says one thing: CAPR is a binary catalyst story where the FDA’s call on deramiocel will likely matter far more than backward‑looking losses.

Why Traders Are Watching CAPR Into The PDUFA Date

Traders are glued to CAPR because the story checks every box of a classic high‑risk, high‑reward biotech setup. Capricor Therapeutics has a single lead program, deramiocel, targeting Duchenne muscular dystrophy (DMD), a brutal disease with huge unmet need. The pivotal HOPE‑3 Phase 3 trial showed a 54% slowing of upper limb function decline versus placebo in largely non‑ambulatory patients, plus meaningful cardiac benefits. Those data are not just internal claims anymore; they are now peer‑reviewed and published in The Lancet, which gives outside validation to both the efficacy signal and the statistical methods.

That publication matters. For CAPR traders, a top‑tier journal review acts like a derisking event. It supports the narrative that the HOPE‑3 trial was well‑run and that the upper‑limb benefit is real, just as the FDA works through the biologics license application. The calendar is clear: the PDUFA action date for deramiocel is set for 2026/08/22, and the BLA remains under active review despite a negative advisory committee vote on the cardiomyopathy indication.

This is where the tug‑of‑war starts. Capricor Therapeutics has publicly disputed parts of the FDA’s briefing documents, saying the agency leaned on an outdated statistical analysis plan (SAP v1.1) instead of the final SAP v3.0 under which HOPE‑3 hit its primary endpoint. Management even published its own slides to push back. That kind of open challenge shows confidence, but it also highlights the regulatory risk: the outcome hinges on how the FDA ultimately interprets the stats.

Wall Street’s reaction is just as split. Oppenheimer kept an Outperform rating on CAPR, arguing the single AdCom question was framed in a way that still favors deramiocel and calling the roughly 70% share drawdown a potentially attractive setup. Cantor Fitzgerald went further, upgrading Capricor Therapeutics to Overweight and lifting its target from $3.50 to $28, signaling belief in a much higher probability of success. On the other side, B. Riley slashed its target to $5 and sits at Neutral, reminding traders that failure risk is real and painful.

Layer on the Q2 2026 update: Capricor Therapeutics reported no revenue, a widening loss, but around $238M in cash and marketable securities and says that cash runway covers at least the next 12 months, not counting any product revenue or Priority Review Voucher sale. That gives CAPR time to reach and potentially move past the FDA decision without an immediate need to raise capital. For momentum and catalyst traders, this mix of strong Phase 3 data, a hard PDUFA date, and polarized analyst calls makes CAPR a stock to watch tick‑by‑tick.

Conclusion

Capricor Therapeutics now sits at a crossroads where science, regulation, and trading psychology collide. On one side, CAPR has deramiocel’s HOPE‑3 data showing a 54% slowdown in upper limb decline and cardiac gains, backed by The Lancet and an active BLA heading into the 2026/08/22 PDUFA date. On the other, the company is still pre‑revenue, bleeding cash, and facing an FDA that already pushed back on its cardiomyopathy claim and questioned elements of its statistics.

The market’s message is simple: this is no longer a quiet clinical story. After the collapse from nearly $20 to the low single digits, CAPR now trades around book value while analysts line up on both sides. Cantor’s $28 target and Overweight rating clash with B. Riley’s $5 Neutral stance, while Oppenheimer highlights what it views as favorable AdCom framing and a potentially overdone selloff. That divergence is exactly what creates volatility and, for disciplined traders, opportunity.

For traders who follow Tim Sykes and Tim Bohen–style rules, the playbook here is clear: treat CAPR as a binary catalyst ticker, not a long‑term comfort blanket. Wait for clear price action around key headlines, respect the risks on both approval and rejection, and keep position sizes in check. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your preparation.” As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. With Capricor Therapeutics, preparation means understanding the HOPE‑3 data, the FDA timeline, and exactly how fast you’re willing to cut losses if the deramiocel story breaks the wrong way.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks